

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
FORSKARPATENT I SYD AB	11/02/2011
RECEIVING PARTY DATA	
Name:	GALECTO BIOTECH AB
Street Address:	C/O ULF NILSSON, SMEDSBOVAGEN 10
City:	LUND
State/Country:	SWEDEN
Postal Code:	225 94
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	12992328
CORRESPONDENCE DATA	
Fax Number:	(312)427-6663
Phone:	3124271300
Email:	debbie.szumowski@ladas.net
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	RICHARD J. STREIT
Address Line 1:	LADAS & PARRY, 224 SOUTH MICHIGAN AVE.
Address Line 4:	CHICAGO, ILLINOIS 60604
ATTORNEY DOCKET NUMBER:	CU-8764 ZBF/DS
NAME OF SUBMITTER:	ZAREEFA B. FLENER
Total Attachments: 4 source=CU-8764 Assignment to Galectin#page1.tif source=CU-8764 Assignment to Galectin#page2.tif source=CU-8764 Assignment to Galectin#page3.tif source=CU-8764 Assignment to Galectin#page4.tif	

CH \$40.00 12992328

PATENT

IPR Assignment Agreement


Agreement	Assignment agreement of IPR related to Galectin research from Forskarpatent i Syd AB, Reg. no. 566528-8940 ("Forskarpatent") to Galecto Biotech AB, Reg. no. 556872-8413 ("Company")
Assignment	Forskarpatent assigns all its Galectin inhibitor rights to the Company
Compensation	Forskarpatent will receive 40,000 (Forty thousand) shares of class A in the Company equal to 40% of the issued shares at the time of signing (Cap table in Appendix B)
Milestone payment and Royalties	Forskarpatent will not be entitled to any milestone payments, royalties or any other form of compensation related to Company's activities with Galectin inhibitors the license agreement
Galectin inhibitor rights	This agreement covers all IP rights regarding Galectin inhibitors currently assigned to Forskarpatent, including but not limited to all the patents and patent applications described in Appendix A
Galectin related contracts	All Forskarpatent contracts (including but not limited to MTAs and research contracts) with third parties related to the Galectin IP rights will be assigned from Forskarpatent to the Company. Forskarpatent has the consent from all inventors to the transfer of galectin rights to Company.
Patent expenses	After signing of Transfer Agreement concerning Galectin IP rights from Forskarpatent to Company, Company will bear all costs to cover expenses related to maintenance of the IP rights.
Additional expenses Patent Transfer Costs	Each party will cover their own expenses related to this agreement. Company will bear all costs associated with transfer of patents from Forskarpatent to Company

Confidentiality	The parties agree to keep this agreement in confidence and not make its content public unless agreed in writing by both parties without the explicit written accept of the other party
Venue	This Agreement shall be governed by the laws of Sweden

Signatures:

For Forskarpatent i Syd AB

Kopparnamn, Nov 22, 2011



Bert Junno, CEO

For Galecto Biotech

Lund, Nov 22, 2011



Hans Schambye, CEO

Appendix A

Galectin 1 Inhibitor (Prio date 2001-01-22)

H0619A-PC-AU Granted patent Australia, Appl. no. 2002 225564

H0619A-PC-CA Patent application Canada, Appl. no. 2 435 363

H0619A-PC-EP Patent application EPC, Appl. no. 02715932.6

H0619A-PC-US Granted patent USA, Appl. no. 10/466 933 – US 7,230,096

Galectin 2 Inhibitor (Prio date 2004-05-21)

I0308A-PC-CA Patent application Canada, Appl. no. 2 567 694

I0308A-PC-EP Patent application EPC, Appl. no. 05745033.0

I0308A-PC-US Granted patent US, Appl. no. 11/561 124

Galectin 3 Inhibitor (Prio date 2004-05-21)

I0308B-PC-CA Patent application Canada, Appl. no. 2 567 700

I0308B-PC-EP Patent application EPC, Appl. no. 05741932.7

I0308B-PC-US Patent application US, Appl. no. 11/561 465

Galectin 4 Synthesis (Prio date 2008-05-16)

M0514A-P-PC Patent application PCT, Appl. no. SE2009/050560

Galectin 5 Inhibitor (Prio date 2009-04-28)

M1229A-US-PROV Provisional patent application, Appl. no. 61/173 284


PATENT

REEL: 027326 FRAME: 0162

Appendix B

	Company Formation			
	A-shares	Total	% ownership (non-diluted)	% ownership (fully diluted)
Ulf Nilsson	17.500	17.500	17,5%	15,9%
Hakon Leffler	17.500	17.500	17,5%	15,9%
Forskarpatent	40.000	40.000	40,0%	36,4%
Hans Schambye	10.000	10.000	10,0%	9,1%
Tariq Sethi	7.000	7.000	7,0%	6,4%
Henrik von Wachenfeldt	2.000	2.000	2,0%	1,8%
Pernilla Sörme	2.000	2.000	2,0%	1,8%
Ian Cumpstey	2.000	2.000	2,0%	1,8%
Bader Salameh	2.000	2.000	2,0%	1,8%
Total shares	100.000	100.000	100,0%	90,9%
Non issued Warrants	7.000	7.000	0,0%	6,4%
Tariq Sethi	3.000	3.000	0,0%	2,7%
Total Warrants	10.000	10.000	0,0%	9,1%
Grand total	110.000	110.000	100,0%	100,0%